Deciphera Pharmaceuticals, Inc. (DCPH)
NASDAQ: DCPH · IEX Real-Time Price · USD
14.65
+0.47 (3.31%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Deciphera Pharmaceuticals Employees
Deciphera Pharmaceuticals had 355 employees on December 31, 2023. The number of employees increased by 55 or 18.33% compared to the previous year.
Employees
355
Change (1Y)
55
Growth (1Y)
18.33%
Revenue / Employee
$460,158
Profits / Employee
-$549,132
Market Cap
1.20B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 355 | 55 | 18.33% |
Dec 31, 2022 | 300 | 20 | 7.14% |
Dec 31, 2021 | 280 | -70 | -20.00% |
Dec 31, 2020 | 350 | 95 | 37.25% |
Dec 31, 2019 | 255 | 141 | 123.68% |
Dec 31, 2018 | 114 | 49 | 75.38% |
Dec 31, 2017 | 65 | 22 | 51.16% |
Jul 31, 2016 | 43 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Phreesia | 1,438 |
Pacira BioSciences | 712 |
AbCellera Biologics | 586 |
Collegium Pharmaceutical | 197 |
Scholar Rock Holding | 150 |
Verona Pharma | 79 |
Ligand Pharmaceuticals | 58 |
DCPH News
- 9 days ago - SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) - PRNewsWire
- 18 days ago - Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum - Business Wire
- 2 months ago - Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results - Business Wire
- 3 months ago - Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024 - Business Wire
- 3 months ago - Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference - Business Wire
- 3 months ago - Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium - Business Wire
- 3 months ago - GENESIS Pharma Announces an Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize RIPRETINIB in 14 EU Markets in Central and Eastern Europe - Business Wire